Sireesh Appajosyula, Director at Hepion Pharmaceuticals, Inc. (HEPA), bought 1,250,000 shares at $0.04 ($50K) on 2026-04-21, disclosed to the SEC on 2026-04-27.
Director Sireesh Appajosyula purchased 1.25 million shares at $0.04, marking the largest insider purchase in Hepion's history. This significant accumulation suggests confidence in the stock's current valuation despite the micro-cap status.
The stock is trading at $0.3181, up 3% over the last 30 days, and is currently sitting at its 52-week high of $0.3181.
The transaction marks the largest insider purchase in company history, potentially signaling strong conviction from leadership.
The stock faces risks from a short interest of 4.1% and a micro-cap market capitalization of approximately $1.75 million, which can lead to high volatility. Additionally, the negative industry insider buying flow of -0.43% over the last 90 days suggests broader sector skepticism.
Something here stands out, but not much.
| Filing → |
| THAR | BUY | 2024-11-13 | $10K | — | Filing → |
| THAR | BUY | 2024-10-09 | $10K | — | Filing → |